YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placebo

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperlipidemia

Conditions

Hyperlipidemia, Hypertension

Trial Timeline

Nov 1, 2013 → Jun 1, 2014

About YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placebo

YH16410 + Rosuvastatin + Telmisartan + YH16410 placebo + Rosuvastatin placebo + Telmisartan placebo is a phase 3 stage product being developed by Yuhan for Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01914432. Target conditions include Hyperlipidemia, Hypertension.

What happened to similar drugs?

6 of 20 similar drugs in Hyperlipidemia were approved

Approved (6) Terminated (1) Active (13)
Diet+pravastatinDaiichi SankyoApproved
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
Rosuvastatin (Crestor)AstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01914432Phase 3Completed

Competing Products

20 competing products in Hyperlipidemia

See all competitors
ProductCompanyStageHype Score
DRL-17822 or placeboDr. Reddy's LaboratoriesPhase 2
32
VK2809 + PlaceboViking TherapeuticsPhase 2
32
YHP1701 + YHR1703 + YHR1704YuhanPhase 3
40
Diet+pravastatinDaiichi SankyoApproved
43
Bempedoic acid 180 mg tabletDaiichi SankyoApproved
43
Minute Maid Heart Wise orange juice + WelcholDaiichi SankyoApproved
43
Pravafen + Pravastatin + FenofibrateShionogiPhase 3
40
Evacetrapib + Atorvastatin + Ezetimibe + PlaceboEli LillyPhase 3
32
exenatideEli LillyPre-clinical
26
LY3015014 IV + Placebo IV + LY3015014 SC + Placebo SCEli LillyPhase 1
29
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injectionsJiangsu Hengrui MedicinePhase 1
33
SHR-1209Jiangsu Hengrui MedicinePhase 1
29
SHR-1209 + PlaceboJiangsu Hengrui MedicinePhase 1/2
32
Rosuvastatin + AtorvastatinAstraZenecaPhase 2
35
Rosuvastatin (Crestor)AstraZenecaApproved
39
simvastatin + EzetimibeMerckApproved
43
MK-0524A + Atorvastatin + SimvastatinMerckPhase 3
40
simvastatin 20 mg/ezetimibeMerckPhase 2/3
38
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for RosuvastatinMerckPhase 3
47
Sitagliptin + PlaceboMerckPhase 2/3
38